Advertisement
Michel Vaudry, SpectraScience's Director of International Sales commentedthat, "We are pleased to have added our second European distributor in thepast two months. Medimar is a respected and well-established medical devicedistributor and its decision to add the WavSTAT Optical Biopsy System to theirportfolio is a strong validation of our technology."
Advertisement
Medimar's President, Francesco Torelli, stated that, "SpectraScience'sWavSTAT cancer diagnosis system has tremendous potential to impact themarketplace here in Italy. The importance of earlier and more effectivescreening for colon cancer cannot be stressed enough and we look forward torepresenting the product and working with SpectraScience to establish andbuild a strong Italian market presence."
Vaudry added that, "Mr. Torelli is a respected thought leader in themedical device market in Italy, so his support of the WavSTAT System will beinstrumental in our acceptance into the major gastroenterology centers in thecountry."
This news release contains forward-looking statements within the meaningof Section 27A of the Securities Act of 1933, as amended, and Section 21E ofthe Securities Exchange Act of 1934, as amended. These forward-lookingstatements involve risks and uncertainties that may cause SpectraScience'sactual results to differ materially from results discussed in forward-lookingstatements. Readers are urged to carefully review and consider the variousdisclosures made by SpectraScience in this news release, its most recent Form10-K and in SpectraScience's other reports filed with the Securities andExchange Commission ("SEC") that attempt to advise interested parties of therisks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and riskfactors filed by SpectraScience in its annual report on Form 10-K and otherdocuments.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs,develops, manufactures and markets spectrophotometry systems capable ofdetermining whether tissue is normal, pre-cancerous or cancerous withoutphysically removing tissue from the body. The WavSTAT Optical Biopsy Systemuses light to optically scan tissue and provides the physician with animmediate analysis. With FDA approval for sale in the U.S. and the CE Mark forthe European Union, the WavSTAT System is the first commercially availableproduct that incorporates this innovative technology for clinical use. TheCompany's LUMA(R) cervical imaging technology has received FDA approval as anoptical non-invasive system that is proven to more effectively detect cervicalcancer precursors than conventional methods available today.Key Benefits to the WavSTAT Optical Biopsy System -- Helps the physician discern between normal and pre-cancerous tissue in the GI tract -- Gives the physician additional information that allows for a more informed decision on leaving polyps on site if they are not pre-cancerous thereby minimizing risks and time. -- Provides the opportunity for physicians to perform a physical biopsy at exactly the same site and time that the optical biopsy is performed -- Allows physicians to determine the margin, or border of the pre-cancerous tissue -- Aids physicians during colon cancer surgery to determine if all cancerous tissue has been removed -- Is complementary to NBI and Smart Pill and other recent evaluating technologies (e.g. Olympus, Pentax, Fujinon, Given).
SOURCE SpectraScience, Inc.
